Overview
- On March 30, 2026, after market hours, Phreesia cut its fiscal 2027 revenue guidance citing worsening visibility and weaker pharmaceutical marketing commitments, and the stock fell about 27% the following day.
- A putative class action filed alleges the company made materially false or misleading statements from May 8, 2025 through March 30, 2026 about its growth outlook and the durability of Network Solutions revenue drivers.
- The complaint says Network Solutions client commitments were already weakening when December 2025 guidance was issued, and it claims the midpoint of guidance later narrowed by roughly $37 million when the shortfall was disclosed.
- Several plaintiff law firms are actively soliciting investors and urging motions to be named lead plaintiff before the July 13, 2026 deadline, with the chosen lead plaintiff to steer discovery, motions and settlement talks.
- The case highlights how recurring pharma marketing commitments drive visibility for healthcare SaaS revenue, and the outcome to watch next is the lead-plaintiff appointment followed by discovery that will test the complaint’s allegations and potential investor recovery.